NANOFORM FINLAND OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.155 EUR | +6.16% |
|
-15.16% | +35.96% |
| Apr. 11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
| Apr. 11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 471.5 | 477.3 | 250.8 | 124.3 | 184.1 | - | - |
| Enterprise Value (EV) 1 | 417.4 | 401.5 | 189 | 124.3 | 153.1 | 162.8 | 169.1 |
| P/E ratio | -20.2 x | -22.7 x | -11 x | -6.1 x | -11.1 x | -15.4 x | -28.7 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 686 x | 239 x | 71.9 x | 48.4 x | 24.6 x | 12.6 x | 7.15 x |
| EV / Revenue | 608 x | 201 x | 54.2 x | 48.4 x | 20.5 x | 11.2 x | 6.57 x |
| EV / EBITDA | -22.9 x | -22.7 x | -9.93 x | -6.34 x | -11.7 x | -20.9 x | -76.7 x |
| EV / FCF | -25.3 x | -18.2 x | -6.47 x | - | 48.6 x | -17.6 x | -28.5 x |
| FCF Yield | -3.95% | -5.5% | -15.5% | - | 2.06% | -5.69% | -3.51% |
| Price to Book | 7.53 x | 5.65 x | 2.88 x | - | 3.42 x | 3.99 x | 3.92 x |
| Nbr of stocks (in thousands) | 66,600 | 72,535 | 78,364 | 78,434 | 85,445 | - | - |
| Reference price 2 | 7.080 | 6.580 | 3.200 | 1.585 | 2.155 | 2.155 | 2.155 |
| Announcement Date | 2/26/21 | 2/22/22 | 2/28/23 | 2/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.687 | 2 | 3.487 | 2.566 | 7.485 | 14.6 | 25.75 |
| EBITDA 1 | -18.2 | -17.7 | -19.03 | -19.6 | -13.06 | -7.795 | -2.205 |
| EBIT 1 | -19.42 | -19.7 | -21.41 | -22.48 | -16.36 | -11.38 | -6.255 |
| Operating Margin | -2,827.22% | -985% | -613.97% | -875.92% | -218.57% | -77.95% | -24.29% |
| Earnings before Tax (EBT) 1 | -19.44 | -19.69 | -22.06 | -20.73 | -15.29 | -11.28 | -6.205 |
| Net income 1 | -19.44 | -19.7 | -22.08 | -20.76 | -15.3 | -11.28 | -6.29 |
| Net margin | -2,829.84% | -985% | -633.07% | -808.89% | -204.48% | -77.26% | -24.43% |
| EPS 2 | -0.3500 | -0.2900 | -0.2900 | -0.2600 | -0.1950 | -0.1400 | -0.0750 |
| Free Cash Flow 1 | -16.49 | -22.09 | -29.21 | - | 3.15 | -9.265 | -5.93 |
| FCF margin | -2,400.63% | -1,104.28% | -837.54% | - | 42.08% | -63.46% | -23.03% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/26/21 | 2/22/22 | 2/28/23 | 2/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.475 | 0.66 | 0.76 | 0.89 | 0.85 | 0.986 | 0.744 | 0.78 | 0.641 | 0.401 | 0.94 | 1.18 | 1.09 | 5.95 |
| EBITDA 1 | -4.615 | -4.8 | -4.6 | -5.484 | -4.19 | -4.784 | -4.493 | -5.372 | -4.38 | -5.353 | -4.38 | -4.06 | -3.67 | -0.31 |
| EBIT 1 | -5.108 | -5.4 | - | -6.07 | -4.8 | -5.43 | -5.148 | -6.103 | -5.102 | -6.122 | -5.13 | -4.9 | -4.5 | -1.2 |
| Operating Margin | -1,075.37% | -818.18% | - | -682.02% | -564.71% | -550.71% | -691.94% | -782.44% | -795.94% | -1,526.68% | -545.74% | -415.25% | -412.84% | -20.17% |
| Earnings before Tax (EBT) 1 | -4.512 | -5.566 | - | -6.055 | -5.151 | -5.57 | - | - | -4.116 | -5.331 | -4.5 | -5.6 | -3.5 | -0.4 |
| Net income 1 | -4.513 | -5.6 | -5.3 | -6.058 | -5.16 | -5.568 | -4.491 | -6.804 | -4.122 | -5.339 | -5.13 | -4.9 | -4.5 | 0.52 |
| Net margin | -950.11% | -848.48% | -697.37% | -680.67% | -607.06% | -564.71% | -603.63% | -872.31% | -643.06% | -1,331.42% | -545.74% | -415.25% | -412.84% | 8.74% |
| EPS | -0.0600 | -0.0800 | -0.0700 | -0.0800 | -0.0700 | -0.0700 | -0.0600 | -0.0900 | -0.0500 | -0.0700 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/25/21 | 2/22/22 | 5/24/22 | 8/25/22 | 11/29/22 | 2/28/23 | 5/25/23 | 8/24/23 | 11/22/23 | 2/29/24 | - | - | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 54.2 | 75.7 | 61.8 | - | 31 | 21.3 | 15 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -16.5 | -22.1 | -29.2 | - | 3.15 | -9.27 | -5.93 |
| ROE (net income / shareholders' equity) | -55.1% | -26.8% | -25.7% | - | -23.4% | -14.7% | 1.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.9400 | 1.160 | 1.110 | - | 0.6300 | 0.5400 | 0.5500 |
| Cash Flow per Share 2 | -0.2500 | -0.2100 | -0.2600 | - | 0.3000 | - | - |
| Capex 1 | 2.34 | 7.74 | 9.13 | - | 2.65 | 3.1 | 4.25 |
| Capex / Sales | 340.06% | 386.84% | 261.7% | - | 35.4% | 21.23% | 16.5% |
| Announcement Date | 2/26/21 | 2/22/22 | 2/28/23 | 2/29/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.155
EUR
Average target price
4.4
EUR
Spread / Average Target
+104.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.96% | 197M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NANOFH Stock
- Financials Nanoform Finland Oyj
